Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

This study shows that BRCA1-deficient cells can give rise to multiple genomically and functionally heterogenous PARPi-resistant clones, which are associated with various vulnerabilities that can be targeted in a mechanism-specific manner. Homologous recombination (HR)-deficient cancers are sensitive to poly-ADP ribose polymerase inhibitors (PARPi), which have shown clinical efficacy in the treatment of high-grade serous cancers (HGSC). However, the majority of patients will relapse, and acquired PARPi resistance is emerging as a pressing clinical problem. Here we generated seven single-cell clones with acquired PARPi resistance derived from a PARPi-sensitive TP53−/− and BRCA1−/− epithelial cell line generated using CRISPR/Cas9. These clones showed diverse resistance mechanisms, and some clones presented with multiple mechanisms of resistance at the same time. Genomic analysis of the clones revealed unique transcriptional and mutational profiles and increased genomic instability in comparison with a PARPi-sensitive cell line. Clonal evolutionary analyses suggested that acquired PARPi resistance arose via clonal selection from an intrinsically unstable and heterogenous cell population in the sensitive cell line, which contained preexisting drug-tolerant cells. Similarly, clonal and spatial heterogeneity in tumor biopsies from a clinical patient with BRCA1-mutant HGSC with acquired PARPi resistance was observed. In an imaging-based drug screening, the clones showed heterogenous responses to targeted therapeutic agents, indicating that not all PARPi-resistant clones can be targeted with just one therapy. Furthermore, PARPi-resistant clones showed mechanism-dependent vulnerabilities to the selected agents, demonstrating that a deeper understanding on the mechanisms of resistance could lead to improved targeting and biomarkers for HGSC with acquired PARPi resistance. Significance: This study shows that BRCA1-deficient cells can give rise to multiple genomically and functionally heterogenous PARPi-resistant clones, which are associated with various vulnerabilities that can be targeted in a mechanism-specific manner.

[1]  G. Adelmant,et al.  TRIP13 regulates DNA repair pathway choice through REV7 conformational change , 2020, Nature Cell Biology.

[2]  E. Winer,et al.  Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer , 2019, bioRxiv.

[3]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[4]  Isidro Cortés-Ciriano,et al.  Detecting the mutational signature of homologous recombination deficiency in clinical samples , 2019, Nature Genetics.

[5]  S. Rottenberg,et al.  Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response , 2018, Genome Medicine.

[6]  A. D’Andrea,et al.  USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors. , 2018, Molecular cell.

[7]  A. D’Andrea.  Mechanisms of PARP inhibitor sensitivity and resistance. , 2018, DNA repair.

[8]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[9]  Joseph V Bonventre,et al.  Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. , 2018, Cancer discovery.

[10]  Marco Mina,et al.  Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability , 2018, PLoS genetics.

[11]  S. Hautaniemi,et al.  Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer. , 2018, Cancer research.

[12]  L. Kauppi,et al.  A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients , 2018, Clinical Cancer Research.

[13]  Chunaram Choudhary,et al.  DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity , 2018, Cell.

[14]  C. Maher,et al.  ClonEvol: clonal ordering and visualization in cancer sequencing , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Marc Hafner,et al.  Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics , 2017, Scientific Data.

[16]  A. D’Andrea,et al.  EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation , 2017, Nature Cell Biology.

[17]  A. Ashworth,et al.  Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance , 2017, bioRxiv.

[18]  L. Borsu,et al.  Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer , 2017, Clinical Cancer Research.

[19]  Kenneth D. Doig,et al.  Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Ramaswamy,et al.  ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells , 2017, Genes & development.

[21]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[22]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[23]  S. Cantor,et al.  Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.

[24]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[25]  Marcel E Dinger,et al.  Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. , 2016, Pathology.

[26]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[27]  Peter Bouwman,et al.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.

[28]  Andrew Menzies,et al.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.

[29]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[30]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[31]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[32]  Michael L Nielsen,et al.  Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. , 2013, Molecular cell.

[33]  G. Shapiro,et al.  Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance , 2013, Proceedings of the National Academy of Sciences.

[34]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[35]  A. Ashworth,et al.  Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study , 2013, Clinical Cancer Research.

[36]  Henry H. Heng,et al.  Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution , 2013, Cancer and Metastasis Reviews.

[37]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[38]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[39]  R. Greenberg,et al.  Links between genome integrity and BRCA1 tumor suppression. , 2012, Trends in biochemical sciences.

[40]  J. Brenton,et al.  Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.

[41]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[44]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[45]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[46]  Rochelle L. Garcia,et al.  Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation , 2007, Molecular Cancer Research.

[47]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.